Observes brexpiprazole use in real-life care for schizophrenia and depression
Follows adults with psychosis or depression who take brexpiprazole in routine care.
Key facts
- Who runs it
- Dr. Albert Kar-Kin Chung
- Where
- Hong Kong, Hong KongSee the site
- Trial code
- Registry title
- Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 1 Jul 2023
- Expected to end
- 31 Dec 2026
- Type of study
- Observational
- Treatments tested
- Brexpiprazole
- Record updated
- 8 July 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 65 with a psychotic or depressive disorder who started brexpiprazole less than 4 weeks ago.
- Age
- 18 to 65 years
- Sex
- All sexes can join.
- Disease stage
- A diagnosis of a psychotic disorder or depression (DSM-5 or ICD-10, codes F10-F19.5, F20-23, F25, F32-F33).
- Earlier treatment
- Must have been receiving brexpiprazole for less than 4 weeks at the time of joining.
Main reasons for not taking part
- Younger than 18 years
- Cannot read English or Chinese
- Cannot give informed consent
- Diagnosed with intellectual disability or mental retardation (ICD-10 F70-73)
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age: 18- 65 years old at the time of enrollment
- Able to read and communicate in English and/or Chinese
- Able to give informed consent
- Has been diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), or International Statistical Classification of Diseases and Related Health Problems 10th revision (ICD-10) to have either Psychotic Disorders (F10-F19.5, F20-23, F25, F32-F33)
- is receiving brexpiprazole as treatment for less than 4 weeks at the time of recruitment
Who cannot take part
- Age <18 years old
- Unable to read English or Chinese
- Unable to give informed consent
- Had been diagnosed to have Intellectual Disabilities (DSM-5) or Mental Retardation (ICD-10 F70-73)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in Hong Kong
- Queen Mary HospitalHong Kong, Hong KongContact: Albert KK ChungTaking people
About the trial
What the trial wants to find out
Not only being the mainstay of treatment for schizophrenia spectrum psychotic disorders, antipsychotics, especially the second-generation antipsychotics (SGAs) have also been recommended as augmenting agents for treating depression. Dopaminergic agents, including both dopamine D2/D3 antagonists and dopamine partial D2 agonists, have been effective for treating psychosis and schizophrenia. Amongst all SGAs, those with partial D2 agonistic property are generally acknowledged to have better side-effect profiles with lower incidence of extrapyramidal side-effects, prolactin increase, weight gain, QTc prolongation, and metabolic syndrome, as well as more efficacious in alleviating depressive symptoms. Up-to-date, three SGAs, namely aripiprazole, brexpiprazole and cariprazine, are known to possess such partial D2 agonism. ReSD-HK study is part of the ReSD Asian Study aiming to carefully evaluate a cohort of patients prescribed with brexpiprazole on its efficacy and tolerability as treatment for schizophrenia and/or depression in a real-life clinical setting.
Treatments tested
- Brexpiprazole
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders: a Naturalistic Non-interventional Prospective Follow-up Study
- Plain-language title
- Observes brexpiprazole use in real-life care for schizophrenia and depressionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05962216, who can take part
- Record updated
- 8 July 2025